Tranzyme Announces DIGEST Trial Stopped After Insufficient Efficacy from Phase 2b Results

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

TranzymePharma (Nasdaq: TZYM) today announced it is discontinuing and immediatelyending patient enrollment in DIGEST, a Phase 2b trial in diabetic patientsreceiving TZP-102 for the management of symptoms of gastroparesis, due toinsufficient efficacy. The decision followed a planned interim futilityanalysis, which examined patients' responsiveness to thrice daily oral dosingof 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial.The results are consistent with the findings of a prior Phase 2b trial in thatthere was a very large placebo effect and no treatment effect.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!